Abstract
Background
This study aimed to evaluate reciprocal interaction between hepatic steatosis (HS) and type 2 diabetes (T2D) through comparative analysis of anti-diabetic treatment, glycemic control, and renal and hepatic function in T2D patients with versus without concomitant HS.
Methods
A total of 102 T2D patients were included in this cross-sectional single-center study, and patients were divided into two groups including those with HS (n = 58) and those without HS (n = 44). Data on patient demographics, current anti-diabetic treatment, and serum levels for fasting blood glucose (FBG), HbA1c (%), urea, creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lipids were recorded.
Results
Diabetic patients with HS had younger age (59.6 ± 10.5 vs. 63.5 ± 14.5 years, p = 0.034) and lower serum urea levels (28.5 (3–61) vs. 39 (14–138), p = 0.012). Metformin (74.1% in patients with HS, 65.9% in patients without HS) was the most frequent anti-diabetic treatment in both groups with similar rate of glycemic control (HbA1c < 7%, 39.7%, and 40.9% of patients, respectively). HbA1c levels were positively correlated with serum urea (r = 0.308, p = 0.042), creatinine (r = 0.306, p = 0.044), and triglyceride (r = 0.358, p = 0.017) levels only in patients without HS. In patients with HS, no significant difference was noted in ALT and AST levels with respect to anti-diabetic regimen. Logistic regression analysis revealed that the presence of proteinuria (OR, 0.327, 95% CI 0.12 to 0.91, p = 0.032) was associated with decreased likelihood of HS in T2D patients.
Conclusion
In conclusion, our findings revealed no increase in the risk of poor glycemic control, dyslipidemia, or nephropathy pertaining to concomitant HS in T2D patients, as well as no difference in ongoing anti-diabetic treatments in terms of serum ALT and AST levels.
Similar content being viewed by others
Availability of data and material
Raw data can be obtained upon request to the corresponding author (teslime.ayaz@erdogan.edu.tr).
References
Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.
Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(2 Suppl. 1):S99–112.
Clark JM, Diehl AM. Hepatic steatosis and type 2 diabetes mellitus. Curr Diab Rep. 2002;2:210–5.
Mills EP, Brown KPD, Smith JD, Vang PW, Trotta K. Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety. Ther Adv Endocrinol Metab. 2018;9:15–28.
Rhee EJ. Nonalcoholic fatty liver disease and diabetes: an epidemiological perspective. Endocrinol Metab (Seoul). 2019;34:226–33.
Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68:335–52.
Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038–48.
Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51:444–50.
Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19:1564–70.
Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, et al. Nonalcoholic fatty liver disease is independently NAFLD and diabetes mellitus associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30:2119–21.
Dawwas GK, Liu X, Nguyen MH. Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study. J Intern Med. 2019;286:711–22.
Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep. 2016;6:33386.
Chinnadurai R, Ritchie J, Green D, Kalra PA. Nonalcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Nephrol Dial Transplant. 2019;34:449–57.
Capone D, Vinciguerra M, Ragosta A, Citro V, Tarantino G. Troponin levels relate to CRP concentrations in patients with NAFLD on maintenance haemodialysis: a retrospective study. Adv Ther. 2020;37:3337–47.
Kang SH, Cho KH, Do JY. Non-alcoholic fatty liver disease is associated with low-grade albuminuria in men without diabetes mellitus. Int J Med Sci. 2019;16:285–91.
Chutani A, Pande S. Correlation of serum creatinine and urea with glycemic index and duration of diabetes in type 1 and type 2 diabetes mellitus: a comparative study. Nat J Physiol Pharm Pharmacol. 2017;7:914–9.
Karningsih TP, Mujianto B, Martini R. The Correlation between the levels of HbA1c with ureum and creatinine in patient with type 2 diabetes mellitus. Asian J Applied Sci. 2019;7:696–700.
Vaishnavi S, Patil S, Sontakke A, Mane D. Study of correlation between HbA1c and renal dysfunction in type-2 diabetes mellitus. Indian J Public Health Res Development. 2019;10:194–9.
Sivasubramanian V, Jetty K, Kumar SS. Correlation of HbA1c with urinary ACR, serum creatinine and eGFR in type-2 diabetes mellitus at Puducherry, South India. Int J Res Med Sci. 2019;7:1924–8.
Farasat T, Sharif S, Naz S, Fazal S. Significant association of serum creatinine with HbA1C in impaired glucose tolerant Pakistani subjects. Pak J Med Sci. 2015;31:991–4.
Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care. 2018;41:372–82.
Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47-64.
Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes - from mechanisms to clinical trials. Metabolism. 2020;111S:154299.
Zhang M, Lin S, Wang MF, Huang JF, Liu SY, Wu SM, et al. Association between NAFLD and risk of prevalent chronic kidney disease: why there is a difference between east and west? BMC Gastroenterol. 2020;20:139.
Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010;59:1410–5.
Zaharia OP, Strassburger K, Strom A, Bönhof GJ, Karusheva Y, Antoniou S, et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol. 2019;7:684–94.
Ahlqvist E, Storm P, Käräjämäki A, Martinell M, Dorkhan M, Carlsson A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a datadriven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361–9.
Nampoothiri RV, Duseja A, Rathi M, Agrawal S, Sachdeva N, Mehta M, et al. Renal dysfunction in patients with nonalcoholic fatty liver disease is related to the presence of diabetes mellitus and severity of liver disease. J Clin Exp Hepatol. 2019;9:22–8.
Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, et al. Association of nonalcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11:e1001680.
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the study of liver diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811–26.
Bhatt HB, Smith RJ. Fatty liver disease in diabetes mellitus. HepatoBiliary Surg Nutr. 2015;4:101–8.
Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Rep. 2013;1:57–64.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
The study was conducted in accordance with the ethical principles stated in the “Declaration of Helsinki” and approved by the institutional ethics committee.
Consent to participate
Written informed consent was obtained from each patient following a detailed explanation of the objectives and protocol of the study which was conducted in accordance with the ethical principles stated in the “Declaration of Helsinki” and approved by the institutional ethics committee.
Consent for publication
The permission was obtained from the institutional ethics committee for the use of patient data for publication purposes.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ayaz, T., Polat, H.B. & Kilictas, B. Evaluation of the reciprocal interaction between hepatic steatosis and type 2 diabetes: a comparative analysis with respect to anti-diabetic treatment, glycemic control, renal and hepatic function. Int J Diabetes Dev Ctries 42, 421–427 (2022). https://doi.org/10.1007/s13410-021-01009-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13410-021-01009-4